CYTK Cytokinetics Incorporated

Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
EN
08/10/2020

Underlying

CYTKCytokinetics Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytokinetics Incorporated

 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertroph...

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers  SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were pr...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides...

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2025. “I’m pleased that our teams continue ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Participate in November Investor Conferences

Cytokinetics to Participate in November Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November: Stifel 2025 Healthcare Conference: Fireside chat on Tuesday, November 11, 2025 at 11:20 AM Eastern Time in New York, NY.Jefferies Global Healthcare Conference: Fireside chat on Monday, November 17, 2025 at 2:30 PM Greenwich Mean Time in London, England. Interested parties may access the live webcas...

November 4, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Card...

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 7, 2025, and at the American Hea...

October 31, 2025 1 EN
 PRESS RELEASE
Free
CYTK Cytokinetics I...

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Cytokinetics to Announce Third Quarter Results on November 5, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at or...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch